6 terminated. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Terminated 6 |
| Phase 2 | 1 | Terminated 1 |
Follow Fallopian Tube Diseases: new trials by email Literature Review of Fallopian Tube Diseases trials Research Report on Fallopian Tube Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2 / Phase 3 | Terminated | Sutro Biopharma, Inc. | 600 | 2023-07-12 | 2025-09-23 |
| Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) Upifitimab rilsodotin, Placebo - High Grade Serous Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Terminated | Mersana Therapeutics | 20 | 2022-06-23 | 2023-10-26 |
| Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin - Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Terminated | Mural Oncology, Inc | 456 | 2022-01-10 | 2025-08-28 |
| Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by talazoparib maintenance, Chemotherapy + bevacizumab followed by bevacizumab - Ovarian Cancer | Phase 3 | Terminated | Pfizer | 79 | 2018-07-19 | 2023-04-06 |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer AMG 386, Paclitaxel, AMG 386 Placebo - Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Terminated | Amgen | 1015 | 2012-01-01 | 2017-02-23 |
| AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) AMG386 plus PLD, Placebo plus PLD - Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Terminated | Amgen | 223 | 2011-04-18 | 2017-12-02 |
Fallopian Tube Neoplasms (6) · Ovarian Neoplasms (6) · Carcinoma, Ovarian Epithelial (2) · Recurrence (1)
Adnexal Diseases (6) · Endocrine Gland Neoplasms (6) · Endocrine System Diseases (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Genital Diseases (6) · Genital Diseases, Female (6) · Genital Neoplasms, Female (6) · Gonadal Disorders (6) · Neoplasms (6) · Neoplasms by Site (6) · Ovarian Diseases (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6)
Paclitaxel (3) · Gemcitabine (2) · Topotecan (2) · liposomal doxorubicin (2) · trebananib (2) · 1-dodecylpyridoxal (1) · Carboplatin (1) · Doxorubicin (1) · Drug Therapy (1) · Taxes (1) · pegfilgrastim (1) · pembrolizumab (1) · talazoparib (1)
Amgen (2) · Mersana Therapeutics (1) · Mural Oncology, Inc (1) · Pfizer (1) · Sutro Biopharma, Inc. (1)
United States (6) · Australia (5) · Canada (5) · Belgium (4) · Italy (4) · Singapore (4) · South Korea (4) · Austria (3) · Germany (3) · Taiwan (3) · Denmark (2) · France (2) · Hong Kong (2) · Japan (2) · New Zealand (2)
PMID 37185961, PMID 31076365, PMID 37334673, PMID 37407274
2009 (1), 2017 (1)